Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.

Mouse

Monoclonal Antibody

Protein G affinity purified

Liquid

ALL

ELISA

ELISA 1:5000-1:20000

Shipped at 4°C. Store at -80℃~-20℃ for two year. Avoid freeze/thaw cycles.

PBS,PH7.4

MMAE conjugated with KLH

1 mg/ml

Unconjugated

IgG1, κ

MM508H

Fig1: ELISA Binding Assay of Anti-MMAE Antibody to different proteins. ELISA analysis of Anti-MMAE Monoclonal Antibody with MMAE-BSA, MMAE ADC and BSA.Anti-MMAE Monoclonal Antibody can bind to MMAE-BSA or MMAE ADC but not carrier protein.

Fig2: ELISA Binding Assay of Anti-MMAE Antibody Immobilized MMAE ADC at 2μg/mL (100μL/well) can bind anti-MMAE mouse monoclonal antibody .